search
Back to results

Chinese Herbal Medicine and Micronized Progesterone for Live Births in Threatened Miscarriage

Primary Purpose

Threatened Miscarriage

Status
Unknown status
Phase
Phase 2
Locations
China
Study Type
Interventional
Intervention
Chinese Herbal Medicine plus Progesterone Capsules
Chinese Herbal Medicine Placebo plus Progesterone Capsules Placebo
Chinese Herbal Medicine plus Progesterone Capsules Placebo
Chinese Herbal Medicine Placebo plus Micronized Progesterone
Sponsored by
Heilongjiang University of Chinese Medicine
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Threatened Miscarriage focused on measuring Threatened Miscarriage, The First Trimester, Micronized Progesterone, Chinese Herbal Medicine, Live Birth

Eligibility Criteria

20 Years - 37 Years (Adult)FemaleDoes not accept healthy volunteers

Inclusion criteria

  1. Age of women between 20-37 years.
  2. Pregnant. The fetus is viable inside the uterine cavity during early pregnancy[1] (5-10 week gestations /35-70 days) as confirmed by positive serum hCG tests and ultrasound, and need to meet either of the following two terms: ① vaginal bleeding with or without abdominal pain, while the cervix is closed by speculum exam; ②Recurrent miscarriage (≥2 prior pregnancy losses including biochemical pregnancy and intrauterine pregnancy loss or a pregnancy loss ≥ 6 weeks from LMP).

Exclusion criteria

  1. Multiple pregnancies (include twin pregnancies).
  2. Ectopic pregnancy. We will define an ectopic pregnancy as any suspected adnexal mass or large amounts of free fluid in the pelvis without an accompanying intrauterine pregnancy.
  3. Pregnancies of Unknown Location (PUL). This will include pregnancies with an hCG level >2500mIU/mL without visualization of an intrauterine or extrauterine (i.e. ectopic) pregnancies.
  4. (4)Non-viable pregnancy. We will define a non-viable pregnancy as: ①an intrauterine pregnancy with a fetal pole without visualized fetal heart motion (>49 days); ②a gestational sac>20 mm in any diameter without a yolk sac; ③absence of a normal gestational sac at 5 weeks of pregnancy, absence of a yolk sac at 5.5-6 weeks of pregnancy, or absence of cardiac activity at 7 weeks of pregnancy by ultrasound; ④falling serum hCG values on serial visits or between baseline and randomization visit, or serial serum hCG levels which show a plateau (2-day increase ≤ 10%).
  5. Intrauterine abnormalities and Fibroids distorting uterine cavity (as assessed by ultrasound).
  6. Bleeding attributed to a vulvar, vaginal, or cervical source unrelated to the pregnancy.
  7. For this threatened miscarriage, use of the same or similar Chinese medicine and/or progesterone more than one week.
  8. Use of agents that may contribute to bleeding such as aspirin, NSAIDs, etc.
  9. Presence of a congenital or acquired bleeding diathesis, i.e. Hemophilia, Von Willebrands's Disease, use of anti-coagulants, etc.
  10. Presence of contributing major medical disorders (regardless of severity). These include poorly controlled diabetes, uncontrolled hypertension, systemic lupus erythematosus (SLE), untreated or active cancer (any cancer in remission or non-melanoma skin cancer is not included in the exclusion criteria), liver disease, renal disease, rheumatoid arthritis, cardiac disease, pulmonary disease other than mild asthma, neurologic disease requiring medical treatment, uncontrolled hypothyroidism, uncontrolled seizure disorder. Untreated vitamin B12 deficiency, severe anemia (hct < 30%), hemophilia, gout, nasal polyps, among others.
  11. Known current or recent alcohol abuse or illicit drug use.
  12. Known abnormal parental karyotype.
  13. Unwilling to give informed consent.
  14. Unwillingness to be randomized and do not want to take daily medications according to the protocol for up to 12 week gestations (84 days).

Sites / Locations

  • Shenzhen Hospital of Beijing UniversityRecruiting
  • Daqing Longnan HospitalRecruiting
  • Xuzhou Central HospitalRecruiting
  • Xuzhou Maternal and Child Health HospitalRecruiting
  • The Second Affiliated Hospital of Jiangxi University of Chinese MedicineRecruiting
  • Dalian Maternity HospitalRecruiting
  • Shanxi Province Hospital of Chinese medicineRecruiting
  • Hangzhou hospital of Chinese medicineRecruiting
  • Wenzhou Hospital of Chinese MedicineRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Placebo Comparator

Experimental

Experimental

Arm Label

CHM+MP

CHM Placebo+MP Placebo

CHM+MP Placebo

CHM Placebo+MP

Arm Description

CHM one dose in the morning and in the evening respectively until 12 weeks of gestations (84 days); MP 100mg tablet by mouth, every 8 hours until 12 weeks of gestations (84 days).

CHM Placebo one dose in the morning and in the evening respectively until 12 weeks of gestations (84 days); MP Placebo 100mg tablet by mouth, every 8 hours until 12 weeks of gestations (84 days).

CHM one dose in the morning and in the evening respectively until 12 weeks of gestations (84 days); MP Placebo 100mg tablet by mouth, every 8 hours until 12 weeks of gestations (84 days).

CHM Placebo one dose in the morning and in the evening respectively until 12 weeks of gestations (84 days); MP 100mg tablet by mouth, every 8 hours until 12 weeks of gestations (84 days).

Outcomes

Primary Outcome Measures

Live birth rate
Cumulative live birth rate

Secondary Outcome Measures

Ongoing pregnancy rate
Cumulative Ongoing pregnancy rate
Ongoing pregnancy rate
Cumulative Ongoing pregnancy rate
Ongoing pregnancy rate
Cumulative Ongoing pregnancy rate
Live birth rate
Cumulative live birth rate
Premature live birth rate
Cumulative Premature live birth rate
Anti-β2 glycoprotein-I antibodies
The number or percentage of Anti-β2 glycoprotein-I antibodies positive patients
Lupus anticoagulant
The number or percentage of Lupus anticoagulant positive patients
Anti-cardiolipin antibody
The number or percentage of Anti-cardiolipin antibody positive patients
Pregnancy loss rate
The number or percentage of patients who have a pregnancy loss
Pregnancy loss rate
The number or percentage of patients who have a pregnancy loss
Serum Progesterone
Value (Units: ng/ml)
Zung Self-Rating Anxiety Scale
Change in scores
SF-12 Health Survey
Change in scores
Adverse event and/or serious adverse event
Pregnancy-induced hypertension, diabetes and antepartum haemorrhage, preterm birth, postdate delivery, preeclampsia and so on

Full Information

First Posted
December 7, 2015
Last Updated
September 22, 2021
Sponsor
Heilongjiang University of Chinese Medicine
search

1. Study Identification

Unique Protocol Identification Number
NCT02633878
Brief Title
Chinese Herbal Medicine and Micronized Progesterone for Live Births in Threatened Miscarriage
Official Title
Chinese Herbal Medicine and Micronized Progesterone for Live Births in Threatened Miscarriage: An International Cooperative Multicenter Randomized Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
September 2021
Overall Recruitment Status
Unknown status
Study Start Date
September 1, 2017 (Actual)
Primary Completion Date
December 31, 2022 (Anticipated)
Study Completion Date
December 31, 2022 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Heilongjiang University of Chinese Medicine

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Threatened miscarriage is manifested by vaginal bleeding, with or without abdominal pain, while the cervix is closed and the fetus is viable and inside the uterine cavity. Threatened miscarriage is a common complication of pregnancy occurring in 20% of all clinically recognized pregnancies and about half of these will eventually result in pregnancy loss. The goal of this double-bind, randomized and double dummy controlled trial is to determine which of the two oral medications, CHM or micronized progesterone, and will mostly likely result in live birth in women with threatened miscarriage. We will evaluate the efficacy and safety of CHM and micronized progesterone for treating threatened miscarriage in this trial. Our primary outcome of this trial is a live birth. We hypothesize that: 1. treatment with CHM plus micronized progesterone placebo or micronized progesterone plus CHM placebo or CHM plus Micronized progesterone is more likely to result in live birth than the control arm which will be CHM placebo plus micronized progesterone placebo; 2. CHM plus micronized progesterone placebo and micronized progesterone plus CHM placebo will have similar treatment effects.
Detailed Description
The causes of spontaneous miscarriage are diverse and comprise chromosomal, genetic, anatomical, immunological, hormonal, infectious and psychological factors, the other factors contribute to an increased risk include advancing paternal and maternal age and mothers with systemic diseases, such as diabetes or thyroid dysfunction. However, the incidence is difficult to determine precisely due to occur very early during a pregnancy and almost 30% of early pregnancy may go unrecognized; the pathogenesis of pregnancy loss in this condition is still remains obscure. Compared with healthy women, the women with threatened miscarriage not only were found to have increased rate of antepartum haemorrhage, prelabour rupture of the membranes, preterm delivery, and intrauterine growth restriction, but also suffer significant psychological impairment including considerable anxiety and stress, depression, sleep disturbances, anger, and marital disturbances. To date, therapies have limited effectiveness in treating threatened miscarriage and are empirical. Bed rest does not prevent pregnancy loss. Acetaminophen may have some effects on relieving pain only. The most commonly used prescription medication was human chorionic gonadotropin (hCG), maintaining the luteotrophic effects to support continued secretion of estrogen and progesterone, However, the beneficial effects of hCG still cannot be verified. Progesterone is another most commonly used traditional medication to treat threatened miscarriage, maintaining the endometrial proliferation and preventing spontaneous pregnancy loss. A number of recent studies in women with threatened miscarriage that has shown a reduction in pregnancy loss with progesterone treatment. Progestogens are a group of hormones, including both the natural female sex hormone progesterone and the synthetic forms. Micronized progesterone is a kind of progesterone; it is structurally and pharmacologically very similar to natural progesterone and has good oral bioavailability. It is especially suitable for women with threatened miscarriage as it does not have androgenic or oestrogenic effects on the foetus. A recent review of maternal use of Micronized progesterone during pregnancy also found no evidence for an increased risk of congenital malformations. However it may only be suitable to treat women with threatened miscarriage who have low progesterone levels due to corpus luteum deficiency at the first trimester pregnancy. There is no evidence to identify the beneficial effects of progesterone to treat threatened miscarriage due to others factors. At the same time, progesterone treatment is also expensive. New or adjuvant treatments that are suitable to treat women with threatened miscarriage due to various factors, and readily accessible, affordable, and safe are needed.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Threatened Miscarriage
Keywords
Threatened Miscarriage, The First Trimester, Micronized Progesterone, Chinese Herbal Medicine, Live Birth

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Factorial Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
1656 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
CHM+MP
Arm Type
Experimental
Arm Description
CHM one dose in the morning and in the evening respectively until 12 weeks of gestations (84 days); MP 100mg tablet by mouth, every 8 hours until 12 weeks of gestations (84 days).
Arm Title
CHM Placebo+MP Placebo
Arm Type
Placebo Comparator
Arm Description
CHM Placebo one dose in the morning and in the evening respectively until 12 weeks of gestations (84 days); MP Placebo 100mg tablet by mouth, every 8 hours until 12 weeks of gestations (84 days).
Arm Title
CHM+MP Placebo
Arm Type
Experimental
Arm Description
CHM one dose in the morning and in the evening respectively until 12 weeks of gestations (84 days); MP Placebo 100mg tablet by mouth, every 8 hours until 12 weeks of gestations (84 days).
Arm Title
CHM Placebo+MP
Arm Type
Experimental
Arm Description
CHM Placebo one dose in the morning and in the evening respectively until 12 weeks of gestations (84 days); MP 100mg tablet by mouth, every 8 hours until 12 weeks of gestations (84 days).
Intervention Type
Drug
Intervention Name(s)
Chinese Herbal Medicine plus Progesterone Capsules
Other Intervention Name(s)
"New Shoutai Pill" plus Micronized Progesterone
Intervention Description
"New Shoutai Pill" Granules plus Micronized Progesterone Capsules
Intervention Type
Drug
Intervention Name(s)
Chinese Herbal Medicine Placebo plus Progesterone Capsules Placebo
Other Intervention Name(s)
"New Shoutai Pill" Placebo plus Micronized Progesterone Placebo
Intervention Description
"New Shoutai Pill" Granules Placebo plus Micronized Progesterone Capsules Placebo
Intervention Type
Drug
Intervention Name(s)
Chinese Herbal Medicine plus Progesterone Capsules Placebo
Other Intervention Name(s)
"New Shoutai Pill" plus Micronized Progesterone Placebo
Intervention Description
"New Shoutai Pill" Granules plus Micronized Progesterone Capsules Placebo
Intervention Type
Drug
Intervention Name(s)
Chinese Herbal Medicine Placebo plus Micronized Progesterone
Other Intervention Name(s)
"New Shoutai Pill" Placebo plus Micronized Progesterone
Intervention Description
"New Shoutai Pill" Granules Placebo plus Micronized Progesterone Capsules
Primary Outcome Measure Information:
Title
Live birth rate
Description
Cumulative live birth rate
Time Frame
>20 weeks of gestation
Secondary Outcome Measure Information:
Title
Ongoing pregnancy rate
Description
Cumulative Ongoing pregnancy rate
Time Frame
Beyond gestation 12 weeks
Title
Ongoing pregnancy rate
Description
Cumulative Ongoing pregnancy rate
Time Frame
Beyond gestation 20 weeks
Title
Ongoing pregnancy rate
Description
Cumulative Ongoing pregnancy rate
Time Frame
Beyond gestation 32 weeks
Title
Live birth rate
Description
Cumulative live birth rate
Time Frame
>37 weeks of gestation
Title
Premature live birth rate
Description
Cumulative Premature live birth rate
Time Frame
>24, but< weeks of gestation
Title
Anti-β2 glycoprotein-I antibodies
Description
The number or percentage of Anti-β2 glycoprotein-I antibodies positive patients
Time Frame
Baseline and end of treatment
Title
Lupus anticoagulant
Description
The number or percentage of Lupus anticoagulant positive patients
Time Frame
Baseline and end of treatment
Title
Anti-cardiolipin antibody
Description
The number or percentage of Anti-cardiolipin antibody positive patients
Time Frame
Baseline and end of treatment
Title
Pregnancy loss rate
Description
The number or percentage of patients who have a pregnancy loss
Time Frame
Before 20 weeks of gestation
Title
Pregnancy loss rate
Description
The number or percentage of patients who have a pregnancy loss
Time Frame
After 20 weeks of gestation
Title
Serum Progesterone
Description
Value (Units: ng/ml)
Time Frame
Baseline, each visit and end of the treatment
Title
Zung Self-Rating Anxiety Scale
Description
Change in scores
Time Frame
Baseline and end of treatment
Title
SF-12 Health Survey
Description
Change in scores
Time Frame
Baseline and end of treatment
Title
Adverse event and/or serious adverse event
Description
Pregnancy-induced hypertension, diabetes and antepartum haemorrhage, preterm birth, postdate delivery, preeclampsia and so on
Time Frame
During treatment, the second and third trimester, postpartum, fetus and newborn

10. Eligibility

Sex
Female
Gender Based
Yes
Gender Eligibility Description
Participants should be in pregnancy
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
37 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria Age of women between 20-37 years. Pregnant. The fetus is viable inside the uterine cavity during early pregnancy[1] (5-10 week gestations /35-70 days) as confirmed by positive serum hCG tests and ultrasound, and need to meet either of the following two terms: ① vaginal bleeding with or without abdominal pain, while the cervix is closed by speculum exam; ②Recurrent miscarriage (≥2 prior pregnancy losses including biochemical pregnancy and intrauterine pregnancy loss or a pregnancy loss ≥ 6 weeks from LMP). Exclusion criteria Multiple pregnancies (include twin pregnancies). Ectopic pregnancy. We will define an ectopic pregnancy as any suspected adnexal mass or large amounts of free fluid in the pelvis without an accompanying intrauterine pregnancy. Pregnancies of Unknown Location (PUL). This will include pregnancies with an hCG level >2500mIU/mL without visualization of an intrauterine or extrauterine (i.e. ectopic) pregnancies. (4)Non-viable pregnancy. We will define a non-viable pregnancy as: ①an intrauterine pregnancy with a fetal pole without visualized fetal heart motion (>49 days); ②a gestational sac>20 mm in any diameter without a yolk sac; ③absence of a normal gestational sac at 5 weeks of pregnancy, absence of a yolk sac at 5.5-6 weeks of pregnancy, or absence of cardiac activity at 7 weeks of pregnancy by ultrasound; ④falling serum hCG values on serial visits or between baseline and randomization visit, or serial serum hCG levels which show a plateau (2-day increase ≤ 10%). Intrauterine abnormalities and Fibroids distorting uterine cavity (as assessed by ultrasound). Bleeding attributed to a vulvar, vaginal, or cervical source unrelated to the pregnancy. For this threatened miscarriage, use of the same or similar Chinese medicine and/or progesterone more than one week. Use of agents that may contribute to bleeding such as aspirin, NSAIDs, etc. Presence of a congenital or acquired bleeding diathesis, i.e. Hemophilia, Von Willebrands's Disease, use of anti-coagulants, etc. Presence of contributing major medical disorders (regardless of severity). These include poorly controlled diabetes, uncontrolled hypertension, systemic lupus erythematosus (SLE), untreated or active cancer (any cancer in remission or non-melanoma skin cancer is not included in the exclusion criteria), liver disease, renal disease, rheumatoid arthritis, cardiac disease, pulmonary disease other than mild asthma, neurologic disease requiring medical treatment, uncontrolled hypothyroidism, uncontrolled seizure disorder. Untreated vitamin B12 deficiency, severe anemia (hct < 30%), hemophilia, gout, nasal polyps, among others. Known current or recent alcohol abuse or illicit drug use. Known abnormal parental karyotype. Unwilling to give informed consent. Unwillingness to be randomized and do not want to take daily medications according to the protocol for up to 12 week gestations (84 days).
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Xiaoke Wu, Ph.D
Phone
+0086-13796025599
Email
xiaokewu2002@vip.sina.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Xiaoke Wu, Ph.D
Organizational Affiliation
First Affiliated Hospital of Heilongjiang Chinese Medicine University
Official's Role
Study Chair
Facility Information:
Facility Name
Shenzhen Hospital of Beijing University
City
Shenzhen
State/Province
Guangdong
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Huiru Tang
First Name & Middle Initial & Last Name & Degree
Huiru Tang
Facility Name
Daqing Longnan Hospital
City
Daqing
State/Province
Heilongjiang
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Xuewu Zhou
First Name & Middle Initial & Last Name & Degree
Xuewu Zhou
Facility Name
Xuzhou Central Hospital
City
Xuzhou
State/Province
Jiangsu
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Bei Zhang
First Name & Middle Initial & Last Name & Degree
Bei Zhang
Facility Name
Xuzhou Maternal and Child Health Hospital
City
Xuzhou
State/Province
Jiangsu
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Zhenxing Hu
First Name & Middle Initial & Last Name & Degree
Zhenxing Hu
Facility Name
The Second Affiliated Hospital of Jiangxi University of Chinese Medicine
City
Nanchang
State/Province
Jiangxi
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ruining Liang
First Name & Middle Initial & Last Name & Degree
Ruining Liang
Facility Name
Dalian Maternity Hospital
City
Dalian
State/Province
Liaoning
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Rui Cao
First Name & Middle Initial & Last Name & Degree
Rui Cao
Facility Name
Shanxi Province Hospital of Chinese medicine
City
Taiyuan
State/Province
Shanxi
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jinfeng Zhang
First Name & Middle Initial & Last Name & Degree
Jinfeng Zhang
Facility Name
Hangzhou hospital of Chinese medicine
City
Hangzhou
State/Province
Zhejiang
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Qin Zhang
First Name & Middle Initial & Last Name & Degree
Qin Zhang
Facility Name
Wenzhou Hospital of Chinese Medicine
City
Wenzhou
State/Province
Zhejiang
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yun Sun
First Name & Middle Initial & Last Name & Degree
Yun Sun

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
Subject's privacy is protected undoubtedly at the time of the informed consent signing

Learn more about this trial

Chinese Herbal Medicine and Micronized Progesterone for Live Births in Threatened Miscarriage

We'll reach out to this number within 24 hrs